Fosun To Fully Acquire Henlius In Go-Global Push?

Hengrui Also In New Alliance

27 May 2024

Parent Fosun and biosimilars arm Henlius halt share trading on the same day, sparking speculation of a buy-out deal that would assist the Chinese firms' globalization push.

Merger and Acquisitions, partnership or work together — Fosun may fully acquire Henlius to boost globalization • Source: Shutterstock

If the swirling speculation proves to be true, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. may become the second large Chinese biopharma group to quickly bolster its commercial portfolio and accelerate overseas expansion through a major corporate transaction.

On 23 May, both Shanghai- and Hong Kong-listed Fosun and its already majority-controlled biotech/biosimilars wing, Hong Kong-listed Shanghai Henlius...